

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


# **Single Technology Appraisal**

Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments ID6363

## **Final Stakeholder List**

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul><li>Company</li><li>Merck Sharp and Dohme (pembrolizumab)</li></ul>	<ul><li>General</li><li>All Wales Therapeutics and Toxicology Centre</li></ul>
l ·	Centre  Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health - Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation NHS Wales Joint Commissioning Committee Scottish Medicines Consortium Welsh Government  Possible comparator companies Abbvie (mirvetuximab soravtansine) Baxter Healthcare (pegylated liposomal doxorubicin hydrochloride) Bristol Myers Squibb (paclitaxel) Genus Pharmaceuticals (paclitaxel) Hospira UK (docetaxel, paclitaxel) Seacross Pharmaceuticals (docetaxel, paclitaxel) Teva UK (paclitaxel)
<ul> <li>Cancer Research UK</li> <li>National Forum of Gynaecological Oncology Nurses</li> </ul>	Biocon Biologics (bevacizumab)     Celltrion Healthcare UK (bevacizumab)

Final stakeholder list for the evaluation of pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments ID6363 Issue date: December 2025



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Obstetricians and Gynaecologists</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> </ul>	<ul> <li>Dr. Reddy's Laboratories (bevacizumab)</li> <li>Organon Pharma (bevacizumab)</li> <li>Pfizer (bevacizumab)</li> <li>Roche (bevacizumab)</li> <li>Thornton &amp; Ross (bevacizumab)</li> <li>Zentiva (bevacizumab)</li> </ul>
<ul> <li>UK Clinical Pharmacy Association</li> <li>UK Oncology Nursing Society</li> <li>Others</li> <li>Department of Health and Social Care</li> <li>NHS England</li> </ul>	<ul> <li>Relevant research groups</li> <li>Genomics England</li> <li>Institute of Cancer Research</li> <li>MRC Clinical Trials Unit</li> <li>National Institute for Health Research</li> </ul> Associated Public Health groups <ul> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

### **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.


#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Final stakeholder list for the evaluation of pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments ID6363





All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.